Our History

M2GEN: Rooted in Science and Cancer Research

M2GEN was spun out of Moffitt Cancer Center, a world-class cancer research institute, to help facilitate a collaborative approach to the fight against cancer. Founded in 2006, M2GEN’s efforts are not only disrupting the way industry researchers look for new cancer therapies, but also developing what the future holds for their approach toward precision cancer medicines.

M2GEN, Total Cancer Care, ORIEN and its leaders have been globally recognized for groundbreaking work in advancing precision medicine. M2GEN is a rapidly growing company, and we continue to expand our data product offerings and scale our capabilities to serve our partners.


The M2GEN Timeline


Our Leadership

M2GEN is led by industry trailblazers and experienced scientific experts who share the belief that the future of effective cancer research and development is rooted in collaboration.

Management Team

Jim Gabriele M2GEN Leadership photo

Jim Gabriele

President and Chief Executive Officer of M2GEN

See Full Bio

Jim Gabriele has more than 30 years’ experience as a senior executive at leading pharmaceutical, medical device and consulting organizations. Most recently, as Senior Vice President and Chief Strategy & Data Science Officer for Medical Devices at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights. Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organization. Previously, Mr. Gabriele built and served as Managing Director and Chief Operating Officer for Henry Rak Consulting Partners, a successful strategy and analytics company serving large global Pharmaceutical, Medical Device and CPG companies. It was acquired by McKinsey & Company and later renamed HRC, where he served as Operating Partner. Mr. Gabriele received a BA in Economics & Government from the College of William & Mary and an MBA from Harvard Business School. He serves on the advisory board of Finpay Holdings.


Eric Anderson

Chief Financial Officer of M2GEN

See Full Bio

Eric Anderson is Chief Financial Officer at M2GEN. He brings more than 25 years of experience across the life sciences, technology, and retail industries.

In this role, Anderson is responsible for the financial, marketing, and sales aspects of M2GEN and provides leadership for the day-to-day financial and operational aspects of the business as the company continues its strategic transformation and accelerates patient impact.

Prior to joining M2GEN, Anderson was CFO at Evidera, a premier RWE and informatics solutions provider to the Biopharma industry. There, he led a global finance and accounting team, built an organic and inorganic playbook to accelerate growth, and deployed new tools and technologies to better empower the finance organization and their business partners.

Previously, Anderson held a variety of senior finance leadership positions at Walmart Inc., including CFO of SamsClub.com, global leader of FP&A for Sam’s Club Stores, and financial leader of digital acceleration for Walmart Inc., where he was responsible for driving expansion of digital, non-retail business models. Anderson has also served in financial and operational leadership roles at Michael’s Stores Inc., FedEx, and IBM. He holds a Bachelor of Science in Finance from the University of Louisville, where he graduated with honors, and serves on the board of several charitable organizations.


Kyle Dunn

Chief Revenue Officer of M2GEN

See Full Bio

Kyle Dunn currently serves as Chief Revenue Officer at M2GEN. In this role, Dunn is responsible for revenue growth within the pharmaceutical and biotechnology customer segment.

Prior to joining M2GEN, Dunn spent over 13 years at NeoGenomics Laboratories, where he served in various leadership roles of increasing responsibility. Most recently, Dunn served as the Vice President, Sales and Commercial Strategy for NeoGenomics’ informatics division where he led a team that developed, commercialized, and sold precision oncology data and analytics solutions for biopharmaceutical and provider organizations across the United States. In prior roles at NeoGenomics, Dunn led teams responsible for standing up scalable processes with academic and government medical centers for reference laboratory testing services that enabled precision oncology data sourcing and collection. He also developed and delivered product roadmaps for next-generation sequencing profiles in solid and hematologic tumors. Dunn has experience developing digital pathology solutions and deploying those solutions into academic medical centers and community hospitals to improve workflow, reduce diagnostic errors and improve patient care.  

Dunn received his Master of Science in Biomedical Diagnostics from Arizona State University and completed his undergraduate work in Business Administration with a concentration in Marketing from California State University, Fullerton. 

DanElgort_m2gen-leadership-photo-2 (003)

Dan Elgort, PhD

Chief Data and Analytics Officer of M2GEN

See Full Bio

Dan Elgort, PhD, currently serves as the Chief Data and Analytics Officer for M2GEN. As both a Fortune 100 leader and entrepreneur, Elgort has spent his career at the intersection of healthcare, technology, and data science delivering unique digital products and services that meaningfully impact patient outcomes. Elgort leads M2GEN's Data & Analytics organization which is responsible for further advancing the end-to-end clinicogenomic data strategy, operations and quality initiatives, and building on the advanced analytics and data science capabilities.

Prior to M2GEN,  Elgort was Chief Scientific Officer at Covera Health, where he built a unique healthcare data platform which collects cancer diagnosis data (e.g., advanced radiological and pathology tissue images), and links that information to longitudinal clinical data including pharmaceutical and surgical interventions. Elgort’s team also was responsible for building advanced analytic products and services designed to help clinicians improve quality of care for patients.  

In his role at Covera, he built a provider data-sharing consortium, established a standardized approach for collecting and linking patient and clinical datasets, and deployed data pipelines and infrastructure to ingest, de-identify, clean, and organize complex data.  In addition, Elgort led development of AI methodologies to deliver health outcome analytic products and services for providers and payors.

Elgort holds baccalaureates in biomedical engineering and computer science from Johns Hopkins University and a Master of Science and Ph.D. in biomedical engineering from Case Western Reserve University.


Maria Mirabal Hipps

Vice President, Legal of M2GEN

See Full Bio

Maria Mirabal Hipps currently serves as Vice President of Legal at M2GEN. Prior to joining M2GEN, Maria was Assistant General Counsel and Real World Solutions Legal Business Partner at IQVIA Inc., a global industry leader in the healthcare data services, technology and clinical research space. In this capacity, Mrs. Mirabal Hipps managed a diverse range of complex legal issues within IQVIA’s Latin America Business Unit ranging from data and technology licensing, to M&A, internal investigations, litigation, privacy and more. A true generalist and trusted business partner, she recently served on the Real World Solutions leadership team as a liaison between the Global Business Unit and Global Legal Team, assisting with operational excellence and contracting matters.

Prior to her 15 year tenure at IQVIA, Mrs. Mirabal Hipps served as an Associate at the New York offices of Brown Raysman Millstien Felder & Steiner LLP.

Mrs. Mirabal Hipps earned a BA from Wesleyan University and a JD from American University, Washington College of Law. She is licensed to practice in New Jersey and New York.


Melissa Honour, MPH

Chief Product Officer of M2GEN

See Full Bio

Melissa Honour, MPH, currently serves as Chief Product Officer at M2GEN. Honour has over 15 years of experience managing products that support provider care delivery, population health, and research.

Honour is an accomplished product management executive with a focus on building high-performing teams and driving commercial strategy with innovation, advanced analytics, and operational excellence. Most recently, she served as Vice President, Product management at Ontada, with responsibility for growing and managing its precision medicine and community oncology portfolio. In this role, she optimized value for both providers and life science customers by building a Product Management organization and roadmap centered on delivering the right information to the right person at the right time. She also expanded product offerings to increase the adoption of genomic ordering and access to results for research.

Honour holds a Bachelor of Science in health psychology from the University of South Florida, a Master of Public Health in epidemiology from the Boston School of Public Health, and a biomedical informatics graduate certificate from Oregon Health Science University.


Todd Johnson, MD

Chief Growth Officer of M2GEN

See Full Bio

Dr. Todd Johnson is Chief Growth Officer for M2GEN. He previously served as Senior Advisor to Clayton, Dubilier & Rice in Healthcare/Real World Data, to which he brought a 20-year track record building and managing high-performing, innovative Life Sciences data and services businesses. His previous experiences include the founding and management of Optum’s Clinical Research Group, co-founding and serving as president and board member at CytoVas, a liquid biopsy company, Noble.MD, an innovative patient data platform sold to WellTrackOne, Abbott Labs/AbbVie’s pharmaceutical pipeline, and MDS / Celerion, a drug development business sold to Bain Capital. Early in his career, Dr. Johnson was a cancer biologist at the Dana-Farber Cancer Institute, and at the Peter Nowell lab at Penn. Dr. Johnson holds a Bachelor of Arts from Penn, an ABA from Oxford, an MD from the Perelman School of Medicine at the University of Pennsylvania, and an MBA from Wharton.


Wilf Russell

Chief Technology Officer of M2GEN

See Full Bio

Wilf Russell is a technical visionary and a high-performing senior executive that brings years of experience and business acumen providing a competitive edge to companies from enterprise to SMBs. His ability to scale, organize, and envision technical strategies amplify unique growth initiatives aligned to changing and accelerating market realities and business expectations. With over 25 years of experience in the software industry building and managing technical organizations across a number of industry verticals, Russell has been responsible for delivery of a wide range of products from mobile apps through highly scalable, cloud-based services and platforms. During his career he has been a leader in a diverse selection of organizations with differing LOB and P&L objectives -- CTO of Nike, Chief Architect of Volvo, the Office of the CTO at Microsoft and IGT, Myspace, Microsoft Research, and RealNetworks – managing large scale operating and capital budgets. Coupled with a strong and clear technical vision and leading organizations of 1500+ employees worldwide, Russell continues to invest in knowledge with a thirst for technology and partners with executive leadership to drive a cohesive engineering roadmap and clear objectives aligned against business and corporate strategies.

Shweta Srikanth Headshot 2 copy

Shweta Srikanth

Head of Strategy & Chief of Staff to the CEO at M2GEN

See Full Bio

Shweta Srikanth serves as Head of Strategy, and Chief of Staff to the CEO at M2GEN. Shweta brings a wealth of experiences across strategic planning and deployment, operational excellence, product marketing and pharmaceutical research. She is passionate about building breakthrough growth strategies and helping executive teams better align strategic choices with everyday operational priorities.

Prior to M2GEN, Shweta held progressive roles at Henkel, where she developed and implemented division and segment strategies; drove product launches and led sales excellence and operational transformation programs. Prior to Henkel, Shweta was a successful Management Consultant at McKinsey & Co. where she counseled pharmaceutical and healthcare diagnostic clients to design and implement lean manufacturing operations. Shweta established her foundational expertise in the pharmaceutical industry as a biochemical engineer at Merck & Co., working on trademark franchises such as VARIVAX® and RotaTeq®.

Shweta holds a Bachelor of Technology in Industrial Biotechnology from Anna University, India, an M.S. in Microbial Engineering from University of Minnesota, and an MBA from the University of Virginia. 

MayYoon_m2gen-leadership-photo (002)

May Yoon

Chief People Officer of M2GEN

See Full Bio

May Yoon currently serves as Chief People Officer at M2GEN. Yoon brings 15 years of experience in human capital management and capability building from her previous roles as Chief People Officer at Agio, a VC-backed IT firm, and at Clear, a biometric identity company. In both roles, Yoon oversaw efforts to successfully develop and deliver end-to-end people strategies to transform company capabilities and drive customer impact and business results. She earned baccalaureate degrees in international relations and psychology from Wellesley College and a Master of Science in management and strategy from the London School of Economics.

Board of Directors


Sandra E. Peterson

Chair of the Board - M2GEN & Partner, Clayton, Dubilier & Rice

See Full Bio

Ms. Peterson joined CD&R in 2019. Prior to CD&R, she was group worldwide chairman of Johnson & Johnson, where she led the consumer and medical devices businesses and was responsible for the corporation’s global supply chain, as well as its technology strategy and operating infrastructure. She currently serves as Chairman of Cynosure. Previously, Ms. Peterson served as CEO of Bayer CropScience AG, CEO of Bayer Medical Care, and president of Bayer HealthCare AG’s Diabetes Care Division. She started her career at McKinsey and has held executive positions at Medco Health Solutions (formerly known as Merck-Medco), Nabisco, and Whirlpool. Ms. Peterson is a member of the Microsoft Board of Directors, chairman of the board of the American Academy in Berlin, and on the board of the Institute for Advanced Study, the world-renowned center for science and humanities research in Princeton, NJ. Ms. Peterson is also on the boards of Covetrus (Nasdaq:CVET), Zymergen, and Volastra. She has appeared on Fortune magazine’s list of most powerful women numerous times and was featured on the magazine’s inaugural list of leaders changing healthcare. She holds an M.P.A. in applied economics from Princeton University and a B.A. in government from Cornell University.


Sarah Kim

Partner - Clayton, Dubilier & Rice (CD&R)

See Full Bio

Ms. Kim joined CD&R in 2008. She played a key role in the Firm’s investments in and subsequent sales of Diversey and naviHealth, the public and secondary offerings of HD Supply and ServiceMaster, and the Firm's investment in Covetrus. Previously, she held positions at private equity firms Metalmark Capital and McCown De Leeuw & Co. and worked in the investment banking division of Goldman Sachs & Co. She currently serves on the board of Huntsworth, a leading provider of specialty services to pharmaceutical and biotech companies. She holds an M.B.A. from Harvard Business School, a J.D. from Harvard Law School (J.D.), and a B.A. in economics and political science from Yale University.

Gregory Dorn, MD, MPH

Senior Vice President - Hearst

See Full Bio

Greg Dorn is a senior vice president of Hearst and the president and group head of Hearst Health, overseeing Hearst’s healthcare businesses in the U.S. and globally, including FDB (First Databank), Zynx Health, MCG, Homecare Homebase and MHK. He also serves as a director of M2Gen and is a member of the Hearst board of directors.

For more than two decades, Dorn has been focused on raising the standard of excellence for patient care across the healthcare spectrum, through clinically rigorous guidance delivered by efficient, scalable technology. He is the co-inventor of two patented healthcare software technologies that continue to be used in health systems across the U.S. His expertise is in developing and commercializing inventive and disruptive solutions that improve care quality and efficiency.

Dorn has held a variety of leadership positions across Hearst, including chief operating officer of Zynx Health and president of FDB. In 2013 he was appointed a vice president of Hearst to lead its growing portfolio of healthcare companies. He became president of Hearst Health in 2014. The mission of Hearst Health is to guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey.

Dorn received his medical doctorate from the Columbia University College of Physicians and Surgeons and his bachelor’s degree from the Columbia University School of Engineering. He performed his clinical training at UCLA, where he also obtained his master’s degree in health services management.


Edmondo Robinson, MD, MBA, FACP

Senior Vice President/Chief Digital Innovation Officer - Moffitt Cancer Center

See Full Bio

Edmondo Robinson, MD, MBA, FACP, serves as the Senior Vice President and Chief Digital Innovation Officer for Moffitt Cancer Center. This newly created position is critical to Moffitt’s success navigating a continually evolving health care industry. Dr. Robinson is responsible for expanding Moffitt’s ecosystem from within and outside of health care to deliver on consumer-oriented, real-world solutions for clinical practice, research and administrative processes essential to support growth and competitive advantage. He also oversees Moffitt’s portfolio of digital innovation, including the development and commercialization of health products, tools and technology. With this role, Moffitt aims to create and test new services, programs, partnerships and technologies that leverage digital innovations, while challenging the status quo to reduce the cost of care, improve quality, increase access to care, and enhance the patient experience.

Previously, Dr. Robinson was the Chief Transformation Officer and Senior Vice President of Consumerism at ChristianaCare, one of the largest health systems in the mid-Atlantic. He was responsible for the transformation of health care delivery to advance population health initiatives and the move from volume-based to value-based care with a special focus on developing and managing ChristianaCare’s consumerism and digital strategies.

Dr. Robinson is an associate professor of medicine at Thomas Jefferson University’s Sidney Kimmel Medical College an adjunct senior fellow in the Leonard Davis Institute of Health Economics at the University of Pennsylvania. He is also a fellow of the American College of Physicians and a senior fellow of the Society of Hospital Medicine. He holds a medical degree from the David Geffen School of Medicine at the University of California, Los Angeles; an MBA with an emphasis in health care management from the Wharton School at the University of Pennsylvania; and a master’s degree in health policy research also from the University of Pennsylvania.


Stuart McGuigan

Former Chief Information Officer - US Department of State

See Full Bio

FrChief Information Officer U.S. Department of State and the Assistant-Secretary level head of the Bureau of Information Resource Management, appointed on March 25, 2019. As Chief Information Officer, he established technology strategic direction and provided oversight for $ 2.4B of technology programs across the Department.

Mr. McGuigan joined the Department of State from Johnson & Johnson where he was responsible for global Information Technology strategy and operations for an organization with 130,000 employees at over 170 overseas and domestic locations. With an established reputation for rapidly aligning technology innovation with global business needs, Mr. McGuigan brings over 33 year of industry background including experience as Senior Vice President and CIO of CVS Caremark, Senior Vice President and CIO of Liberty Mutual, and Senior Vice President of Information Services for Medco Health Solutions.

Mr. McGuigan earned Master of Science and Master of Philosophy degrees in the Cognitive Science program at Yale University, and has a Bachelor of Arts degree in psychology from Fairfield University. In 2018, Mr. McGuigan was inducted into www.CIO.com’s CIO Hall of Fame, and he is the recipient of the “Lifetime Contribution Award” from NASSCOM—India’s top not-for-profit IT organization, enabling India’s growth of its $154 billion dollar IT-Business Process Management (BPM) industry.


Anand Shah, MD

Former Deputy Commissioner for Medical and Scientific Affairs - U.S. Food & Drug Administration

See Full Bio

Anand Shah, M.D. is a nationally recognized physician leader and health policy expert who most recently served as the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration (FDA). Dr. Shah’s efforts have focused on bringing new technologies to market, redesigning health care delivery and economic incentives, and expanding competition and consumer choice. At FDA, Dr. Shah led consensus policy development for fit-for-purpose programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, COVID-19 vaccine development, digital health, consumer protection, and decentralized clinical trials. He developed a science and technology incubator designed to harness real-world evidence and artificial intelligence to improve health outcomes. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Governors, and local governments. He regularly briefed bipartisan bicameral Congressional leadership on the formulation of public health policies and programs.

He previously served in two senior leadership roles at the Centers for Medicare & Medicaid Services (CMS). As Senior Medical Advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. Dr. Shah established consensus on several critical policy initiatives including aligning payment and prevention to increase Medicare beneficiaries’ access to novel antimicrobials, expanding patients’ access to cell and gene therapies, and streamlining Medicare access to breakthrough technologies. As the Chief Medical Officer of the Center for Medicare & Medicaid Innovation (CMMI), Dr. Shah led the clinical design of novel value-based payment and service delivery models including those for advanced primary care, specialty care, and prescription drugs.

Dr. Shah specializes in the early detection, surveillance, and treatment of prostate cancer. He developed and led an NIH survivorship clinic in the care of patients on cancer clinical trials. He has served as an Adjunct Senior Fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania. Dr. Shah completed a health economics fellowship at the University of Pennsylvania where he developed and applied significant expertise with economic, financial, and valuation modeling of emerging therapeutics. Dr. Shah was on Duke University faculty where he led the Center for Excellence in Surgical Outcomes as its Associate Director. He has received research funding from government and philanthropic sources. His scientific track record includes publications in the New England Journal of Medicine, JAMA, Health Affairs, Cancer, and Nature Reviews Drug Discovery.

Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah graduated with honors from Duke University with a degree in economics. He also served as a Canada-U.S. Fulbright Scholar.

Board Observers

Raphael Pollock, MD, PhD, FACS

Director, the Ohio State University Comprehensive Cancer Center Kathleen Wellenreiter Klotz Chair in Cancer Research

See Full Bio

Raphael E. Pollock, MD, PhD was born in Chicago, IL in 1950. He is a graduate of Oberlin College in Oberlin, OH, where he majored in history. This was followed by medical school at St. Louis University, St. Louis; MO, residency training in general surgery at Rush-Presbyterian-St. Luke’s Medical Center and the University of Chicago Hospitals and Clinics, Chicago, IL; followed by fellowship training in surgical oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Pollock was invited to join the MD Anderson faculty in 1984 upon completion of fellowship training. While serving as an assistant professor of surgery, Dr. Pollock began graduate studies at the University of Texas Health Science Center/Houston, Graduate School of Biomedical Sciences, culminating in receipt of the PhD in tumor immunology in 1990. In 1993 Dr. Pollock began service as chairman of the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, a position that he held until 2010. In 1996, service as head of the Division of Surgery at the University of Texas MD Anderson Cancer Center was begun, a position entailing supervisory relationships with all 7 surgical specialty departments at that institution. In 2013 Dr. Pollock was recruited to Ohio State University as professor and director of the Division of Surgical Oncology and Chief of Surgical Services at the James Comprehensive Cancer Center. This was followed by appointment in 2015 as Surgeon in Chief, the James Comprehensive Cancer Center and Surgeon in Chief, the Ohio State University Health System. In 2017, Dr. Pollock was appointed to his current position as professor and director of the Ohio State University Comprehensive Cancer Center.

Dr. Pollock’s clinical and laboratory research work focuses on soft tissue sarcoma, a rare tumor system of connective tissue origin. He has been the recipient as principal investigator of an NIH/NCI K08 Clinician-Investigator Award (1984-89), an NIH/NCI R29 FIRST Award (1989-1994), an NIH/NCI R01 Award (1995-2007), and NIH/NCI T32 Training Grant (1999-2010), and an NIH/NCI SPORE award (2012-2017). He is married to Dina Lev, MD, a Professor of Surgery at Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel. They have 5 children: Jessica, a medical student at the Ohio State University College of Medicine; Samuel and Eden, students at the Ohio State University College of Arts and Sciences; and Noam and Omer, who are in high school in Tel Aviv, Israel.

David M. Rubin, PhD

Managing Director and Founding Partner, Merck Global Health Innovation Fund

See Full Bio

David M. Rubin, Ph.D., is a Managing Director and a founding partner of GHI Fund since inception in 2010. David is focused on digital health and precision medicine mainly focused in oncology. David has spent more than 30 years in the healthcare industry. Before joining the GHI team, Dr. Rubin led a portfolio management group in Merck Research Labs, where he facilitated the development of franchise strategies and analysis of portfolio valuations. David joined Merck from Cognia Corporation, a venture-backed international healthcare R&D software company, where he was CEO. Previously, Dr. Rubin was a management consultant at The Wilkerson Group/IBM Global Services. Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University

Dave Schulte

Senior Vice President and Managing Director of McKesson Ventures

See Full Bio

Dave is Senior Vice President and Managing Director of McKesson Ventures.  He has been investing in innovative healthcare businesses for nearly two decades.  Prior to McKesson, Dave ran Kaiser Permanente Ventures and helped build the investment program from $20M to $400M of assets under management.  Prior to KP Ventures, he spent several years in healthcare and technology investment banking at JPMorgan, UBS and Piper Jaffray.  He is a graduate of St. John's University (MN) and earned a Master of Public Policy degree from Harvard University.

Interested in Joining the M2GEN team?

Learn More